NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells

• Johnny Torres

 Aberrant NOTCH3 signaling and overexpression is oncogenic, related with most cancers stem cells and drug resistance, but therapeutic concentrating on stays elusive. Right here, we develop NOTCH3-targeted antibody drug conjugates (NOTCH3-ADCs) by bioconjugation of an auristatin microtubule inhibitor via a protease cleavable linker to 2 antibodies with differential skills to inhibit signaling. The signaling inhibitory…